The Effect of Vasopressor on Pressure Injury Development

• Status: Completed
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Background: Vasopressors are life-saving agents that increase mean arterial pressure. The pharmacodynamic features of these agents and previous studies suggest that vasopressors may be an essential risk factor in developing pressure injuries.

Objective: This study aimed to examine the effect of vasopressors in medical-surgical intensive care patients on pressure injury development.

Design and Settings: This retrospective and correlational study was conducted between March 2021- May 2022. The electronic patient data were obtained from 148 surgical and medical patients treated with vasopressor agents in the intensive care unit. Data on patients' demographic and clinical characteristics were evaluated using descriptive statistical methods (number, percentage, mean, standard deviation). A logistic regression model was established to estimate the dependent variable (development of pressure injury) with the independent variables.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Koç University
• Treatments: Dopamine; Norepinephrine

Criteria

Inclusion Criteria:

The sample consisted of all:

• Medical and surgical patients over 18 who do not have pressure injury upon admission

• Received one or more vasopressor agent infusions (norepinephrine, epinephrine, phenylephrine, dopamine, adrenaline, dobutamine) for at least 48 hours during their stay in the intensive care unit

Exclusion Criteria:

• patients less than 18 years old

• less than 48 hours stay in intensive care unit

• did not receive ant vasospressor agents